Compare GBLI & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GBLI | IVVD |
|---|---|---|
| Founded | 2016 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 395.4M | 437.1M |
| IPO Year | 2010 | 2021 |
| Metric | GBLI | IVVD |
|---|---|---|
| Price | $26.94 | $1.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.75 |
| AVG Volume (30 Days) | 3.8K | ★ 2.5M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 5.13% | N/A |
| EPS Growth | N/A | ★ 79.02 |
| EPS | ★ 0.29 | N/A |
| Revenue | ★ $450,098,000.00 | $53,426,000.00 |
| Revenue This Year | $14.23 | $61.57 |
| Revenue Next Year | $9.68 | $41.42 |
| P/E Ratio | $92.88 | ★ N/A |
| Revenue Growth | 2.02 | ★ 110.47 |
| 52 Week Low | $25.63 | $0.49 |
| 52 Week High | $34.00 | $3.07 |
| Indicator | GBLI | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 44.00 | 36.10 |
| Support Level | $25.76 | $1.05 |
| Resistance Level | $29.07 | $1.14 |
| Average True Range (ATR) | 0.45 | 0.10 |
| MACD | -0.06 | -0.02 |
| Stochastic Oscillator | 40.85 | 16.22 |
Global Indemnity Group LLC is a United States-based holding company with a diversified portfolio of property and casualty insurance-related entities. Along with its subsidiaries, the company operates in the following reportable segments: Agency and Insurance Services, Belmont Insurance Companies - Core (Belmont Core), and Belmont Insurance Companies - Non-Core (Belmont Non-Core). Maximum revenue is generated from the Belmont Core segment, which offers direct insurance and assumed reinsurance products in the E&S (Excess and Surplus) marketplace. The Agency and Insurance Services segment is focused on sourcing, underwriting, and servicing primary and assumed reinsurance business; and specialized insurance service businesses providing technology, AI-enabled marketplace, and claims services.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.